# Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

> **NCT03978624** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Entinostat
- **PROCEDURE:** Procedure/Surgery

## Key facts

- **NCT ID:** NCT03978624
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-23
- **Primary completion:** 2024-03-25
- **Final completion:** 2026-11-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03978624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03978624, "Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03978624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*